Overview of the Klemperer Lecture: Dr. Kathryn Dao
Dr. Dao summarizes the Klemperer lecture on pre-clinical lupus as presented at the 2019 ACR/ARP Annual Meeting in Atlanta.
Will Reduction of RF affect Erosions in RA (Abstract #464): Dr. Janet Pope
Dr. Pope discusses Abstract #464 at the 2019 ACR/ARP annual meeting in Atlanta.
Interview with Dr. John Reveille: Dr. Kanika Monga
Dr. Kanika Monga interviews new ACR Master Dr. John Reveille, who offers his advice on a career in rheumatology, how the field has changed, what he looks forward to at the 2019 meeting, and a preview of his Hench lecture.
Psoriatic Arthritis and Guselkumab: Dr. Eric Ruderman
Dr. Ruderman discusses guselkumab studies presented at the 2019 ACR/ARP annual meeting in Atlanta.
PANLAR Recommendations on Imaging Studies for Gout: Dr. Olga Petryna
Dr. Petryna reviews PANLAR's recommendations on imaging studies for gout at the 2019 ACR/ARP annual meeting in Atlanta.
It has been a wonderful year for autoinflammatory diseases at the ACR Annual Meeting.
I attended my first ACR Annual Meeting in 2011 in Chicago. In that meeting, there were 29 abstracts on autoinflammatory diseases and there were no sessions exclusively focusing on that topic*.
Clinical Infection Risk and Safety Profiles in RA: Dr. Kathryn Dao
Dr. Dao summarizes a number of studies presented on infection risk and safety profile in RA at the 2019 ACR/ARP annual meeting in Atlanta.
MACE + VTE Across Upadacitinib Studies in RA Patients: Dr. Jonathan Kay
Dr. Kay discusses major adverse cardiovasular events in patients with RA at the 2019 ACR/ARP annual meeting in Atlanta.
igG4-Related Diseases: Dr. David Liew
Dr. David Liew discusses an interesting poster on igG4-related disease at the 2019 ACR/ARP annual meeting in Atlanta.
Biosimilars: Dr. Arthur Kavanaugh
Dr. Kavanaugh discusses biosimilar studies being presented at the 2019 ACR/ARP annual meeting in Atlanta.
Upadacitinib in RA: Dr. Cassandra Calabrese
Dr. Calabrese discusses abstract #547 and abstract #509 as presented at the ACR/ARP annual meeting in Atlanta.
Panel Presentation: The X Factor
Drs. Rachel Tate, Kathryn Dao, Kanika Monga, Courtney Crayne, and Arundathi Jayatillekey discuss issues, ideas and opportunities around the topic of women in rheumatology, with special guest Dr. Eric Ruderman, at the 2019 ACR/ARP Annual Meeting in Atlanta.
Everyone has life hacks. Years of experience and doing the same things repetitively allow us to figure out little tricks to make life easier. A rat in a maze, finding itself at a dead end, will back up and search for a clearing. If this rat encounters its neighbor, it will transmit that information so the second rat won’t make the same mistake.
There were new developments in the treatment of axial Spondyloarthritis (AS) at ACR 2019. The first area is on the use of anti-IL17A drugs, secukinumab and ixekizumab in non-radiographic AS. The second area is the use of JAK-1 inhibitor Upadacitinib in radiographic AS. The third area is the use of dual anti-IL17A and 17F drug bimekizumab in radiographic.
Dr. John Cush RheumNow
6 years 11 months ago
The FDA has approved Pfizers new adadliumab biosimilar - Abrilada (adalimumab-afzb), this is the 5th adalimumab biosimilar to be approved (none are commercially available in the USA until 2023). Abrilada is the 25th biosimilar approved in the U.S. https://t.co/Z0tp3D5yOd
